RoActemra® (tocilizumab) Dosing for Rheumatoid Arthritis (RA)

This material is provided by Roche Products Limited as a licence requirement for this medicine and forms part of the Risk Management Plan

RoActemra is available in three different dosing vials:

400 mg (20 ml) 200 mg (10 ml) 80 mg (4 ml)

8 mg/kg

Weight (kg)	Weight (lbs)	Dose (mg)	Dose (ml)	Vial combinations
50	110.0	400	20.0	400
52	114.4	416	20.8	400 + 80
54	118.8	432	21.6	400 + 80
56	123.2	448	22.4	400 + 80
58	127.6	464	23.2	400 + 80
60	132.0	480	24.0	400 + 80
62	136.4	496	24.8	200 + 80 + 80 + 80 + 80
64	140.8	512	25.6	200 + 80 + 80 + 80 + 80
66	145.2	528	26.4	400 + 80 + 80
68	149.6	544	27.2	400 + 80 + 80
70	154.0	560	28.0	400 + 80 + 80
72	158.4	576	28.8	400 + 200
74	162.8	592	29.6	400 + 200
76	167.2	608	30.4	400 + 80 + 80 + 80
78	171.6	624	31.2	400 + 80 + 80 + 80
80	176.0	640	32.0	400 + 80 + 80 + 80
82	180.4	656	32.8	400 + 200 + 80
84	184.8	672	33.6	400 + 200 + 80
86	189.2	688	34.4	400 + 80 + 80 + 80 + 80
88	193.6	704	35.2	400 + 80 + 80 + 80 + 80
90	198.0	720	36.0	400 + 80 + 80 + 80 + 80
92	202.4	736	36.8	400 + 200 + 80 + 80
94	206.8	752	37.6	400 + 200 + 80 + 80
96	211.2	768	38.4	400 + 400
98	215.6	784	39.2	400 + 400
≥100	≥220.0	800	40.0	400 + 400

Dosing calculation: **Patient's weight (kg) x 8 (mg/kg) = RoActemra dose.**
For individuals whose body weight is more than 100 kg, doses exceeding 800 mg per infusion are not recommended.

1. Calculate the appropriate dose

RoActemra dosing is calculated based on the individual patient's weight. Verify the patient's weight and then locate it on the chart to find the corresponding dose and recommended vial combination.

If the dose has been previously calculated, check the patient's weight to make sure a dosage change is not needed. If there has been a significant change in weight, please consult the prescriber.

2. Choose the vial combination of RoActemra that best matches your patient's needs

RoActemra is available in three different dosing vials:

400 mg (20 ml) 200 mg (10 ml) 80 mg (4 ml)

RoActemra is administered as a 60-minute, IV infusion at 4-week intervals.

Infusion reactions

During the infusion, watch the patient closely for any signs and symptoms of hypersensitivity, including anaphylaxis. If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and permanently discontinued. Fatal anaphylaxis has been reported during treatment with RoActemra.

Full prescribing information can be found in the RoActemra Summary of Product Characteristics (SmPC) via the electronic Medicines Compendium (eMC) website: www.medicines.org.uk.

If you have any further questions relating to RoActemra please contact Roche Medical Information on +44 (0)800 3281629 or email: medinfo.uk@roche.com.

Roche

Suspected adverse reactions associated with the use of RoActemra should be reported to: Medicines Authority Post-licensing Directorate 203. Level 3. Rue D'Argens, Gzira GZR 1368, or at: http://www.medicinesauthority.gov.mt/adrportal. Suspected adverse events should also be reported to Roche by phone on +44 (0)1707 367554, fax on +44 (0)1707 367582 or e-mail at welwyn.uk_dsc@roche.com.

RXUKACTE00018 July 2013